| Literature DB >> 24742150 |
Gábor Németh1, Zoltán Greff, Anna Sipos, Zoltán Varga, Rita Székely, Mónika Sebestyén, Zsuzsa Jászay, Szabolcs Béni, Zoltán Nemes, Jean-Luc Pirat, Jean-Noël Volle, David Virieux, Ágnes Gyuris, Katalin Kelemenics, Eva Ay, Janos Minarovits, Susan Szathmary, György Kéri, László Orfi.
Abstract
Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24742150 DOI: 10.1021/jm401742r
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446